Qiagen has announced its financial results for the first quarter of 2017, during which it delivered a net sales total of $307.7 million (237.42 million pounds).
This represents a year-on-year increase of three percent, while its adjusted earnings per share came to $0.21 at constant exchange rates, meaning the company met its growth goals on both metrics.
“Qiagen has met its financial goals in terms of sales and earnings growth during the first quarter of 2017.“
All customer classes and regions contributed to this performance, with key products such as QuantiFERON-TB, the QIAsymphony system and the GeneReader NGS system all seeing strong results.
The firm also launched the first US-approved assay for variants in the JAK2 gene to help diagnose a form of leukaemia, while completing a deal to acquire OmicSoft in January.
Over the whole of 2017, Qiagen is hoping to support more than 500,000 customers and deliver sales growth of between six and seven percent.
Peer Schatz, chief executive officer of Qiagen, said: "Qiagen delivered a good start into 2017, and this has reaffirmed our confidence in achieving full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share."
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Science